1. Exploring cellular diversity in lung adenocarcinoma epithelium: Advancing prognostic methods and immunotherapeutic strategies.
- Author
-
Zhang L, Cui Y, Mei J, Zhang Z, and Zhang P
- Subjects
- Humans, Prognosis, Epithelium pathology, Epithelium metabolism, Epithelium immunology, CDC2-CDC28 Kinases genetics, CDC2-CDC28 Kinases metabolism, Adenocarcinoma of Lung immunology, Adenocarcinoma of Lung pathology, Adenocarcinoma of Lung genetics, Adenocarcinoma of Lung therapy, Immunotherapy methods, Lung Neoplasms pathology, Lung Neoplasms therapy, Lung Neoplasms immunology, Lung Neoplasms genetics, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism
- Abstract
Immunotherapy has brought significant advancements in the treatment of lung adenocarcinoma (LUAD), but identifying suitable candidates remains challenging. In this study, we investigated tumour cell heterogeneity using extensive single-cell data and explored the impact of different tumour cell cluster abundances on immunotherapy in the POPLAR and OAK immunotherapy cohorts. Notably, we found a significant correlation between CKS1B+ tumour cell abundance and treatment response, as well as stemness potential. Leveraging marker genes from the CKS1B+ tumour cell cluster, we employed machine learning algorithms to establish a prognostic and immunotherapeutic signature (PIS) for LUAD. In multiple cohorts, PIS outperformed 144 previously published signatures in predicting LUAD prognosis. Importantly, PIS reliably predicted genomic alterations, chemotherapy sensitivity and immunotherapy responses. Immunohistochemistry validated lower expression of immune markers in the low-PIS group, while in vitro experiments underscored the role of the key gene PSMB7 in LUAD progression. In conclusion, PIS represents a novel biomarker facilitating the selection of suitable LUAD patients for immunotherapy, ultimately improving prognosis and guiding clinical decisions., (© 2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF